Replies to post #90620 on Biotech Values

[genisi]

IP is a problem with Treands as Bendamustine was discovered and marketed in EU ages ago and has no CoM patent protection. It has 5 years of exclusivity due to Hatch-Waxman NCE regulations, plus as you know Cephalon is also trying to enhance Treanda IP and and several patent applications are pending at the USPTO.